{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:55:29Z","timestamp":1792652129781,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.neuropharm.2017.10.032","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T01:01:38Z","timestamp":1509066098000},"page":"351-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders"],"prefix":"10.1016","volume":"128","author":[{"given":"Robert F.","family":"Bruns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen N.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Wafford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1425-5015","authenticated-orcid":false,"given":"Alex J.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine A.","family":"Shanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey K.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Eastwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Schaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junliang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Witkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyassu","family":"Chernet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Katner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-581X","authenticated-orcid":false,"given":"Meghane E.","family":"Masquelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda K.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick L.","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna L.","family":"Maren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie F.","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell A.","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.10.032_bib1","first-page":"166","article-title":"Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us","volume":"2","author":"Abi-Dargham","year":"2003","journal-title":"World Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0014-2999(90)90240-7","article-title":"Discriminatory roles for D1 and D2 dopamine receptor subtypes in the in\u00a0vivo control of neostriatal cyclic GMP","volume":"181","author":"Altar","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00426210","article-title":"Effects of scopolamine, d-amphetamine and other drugs affecting catecholamines on spontaneous alternation and locomotor activity in mice","volume":"45","author":"Anisman","year":"1975","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib4","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/cercor\/bht195","article-title":"The neurobiology of thought: the groundbreaking discoveries of Patricia Goldman-Rakic 1937\u20132003","volume":"123","author":"Arnsten","year":"2013","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.biopsych.2015.12.028","article-title":"Novel dopamine therapeutics for cognitive deficits in schizophrenia","volume":"81","author":"Arnsten","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib6","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/oby.2007.205","article-title":"Randomized controlled trials of the D1\/D5 antagonist ecopipam for weight loss in obese subjects","volume":"15","author":"Astrup","year":"2007","journal-title":"Obesity"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib7","unstructured":"Beadle CD, Coates DA, Hao J, Krushinski JH, Reinhard MR, Schaus JM and Wolfangel CD (2014) 3,4-dihydroisoquinolin-2(1H)-yl compounds WO 2014\/193781 A1, pp\u00a01\u201390."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1124\/pr.110.002642","article-title":"The physiology, signaling, and pharmacology of dopamine receptors","volume":"63","author":"Beaulieu","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.tins.2007.03.004","article-title":"Fifty years of dopamine research","volume":"30","author":"Bjorklund","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1471-4159.1987.tb05591.x","article-title":"Modulation of in\u00a0vivo dopamine release by D2 but not D1 receptor agonists and antagonists","volume":"48","author":"Boyar","year":"1987","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00002826-199310000-00002","article-title":"Neurobiological mechanisms involved in antidepressant therapies","volume":"16","author":"Briley","year":"1993","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1126\/science.127.3296.471","article-title":"On the presence of 3-hydroxytyramine in brain","volume":"127","author":"Carlsson","year":"1958","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib13","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1523\/JNEUROSCI.0491-06.2006","article-title":"Behavioral and molecular effects of dopamine D1 receptor stimulation during naloxone-precipitated morphine withdrawal","volume":"26","author":"Chartoff","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib14","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/j.1471-4159.1992.tb08473.x","article-title":"Endogenous dopamine facilitates striatal in\u00a0vivo acetylcholine release by acting on D1 receptors localized in the striatum","volume":"59","author":"Consolo","year":"1992","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib15","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.6338589","article-title":"Alzheimer's disease: a disorder of cortical cholinergic innervation","volume":"219","author":"Coyle","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib16","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0014-2999(90)90456-G","article-title":"Dopamine D1 receptor stimulation increases striatal acetylcholine release in the rat","volume":"186","author":"Damsma","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/(SICI)1098-2396(199703)25:3<227::AID-SYN1>3.0.CO;2-D","article-title":"NMDA and D1 receptors regulate the phosphorylation of CREB and the induction of c-fos in striatal neurons in primary culture","volume":"25","author":"Das","year":"1997","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/0306-4522(93)90235-8","article-title":"Dopaminergic regulation of cortical acetylcholine release: effects of dopamine receptor agonists","volume":"54","author":"Day","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib20","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/jnnp.64.3.320","article-title":"Spontaneous and reflex activity of facial muscles in dystonia, Parkinson's disease, and in normal subjects","volume":"64","author":"Deuschl","year":"1998","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0022-3956(03)00007-4","article-title":"Selective alterations of the first NREM sleep cycle in humans by a dopamine D1 receptor antagonist (NNC-687)","volume":"37","author":"Eder","year":"2003","journal-title":"J.\u00a0Psychiatric Res."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib22","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"supplement 1","key":"10.1016\/j.neuropharm.2017.10.032_bib23","first-page":"707","article-title":"Neurochemical profile of a novel allosteric potentiator of the dopamine D1 receptor","volume":"30","author":"Falcone","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.110.172957","volume":"336","author":"Fell","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3565(24)36980-0","article-title":"Characterization of unconditioned behavioral effects of dopamine D3\/D2 receptor agonists","volume":"283","author":"Geter-Douglass","year":"1997","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1527-3458.2001.tb00201.x","article-title":"Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data","volume":"7","author":"Giardina","year":"2001","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-004-1793-y","article-title":"Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction","volume":"174","author":"Goldman-Rakic","year":"2004","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0165-0173(99)00045-4","article-title":"D1 receptors in prefrontal cells and circuits","volume":"31","author":"Goldman-Rakic","year":"2000","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0022-3565(24)38751-8","article-title":"Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease","volume":"296","author":"Gulwadi","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0169-328X(00)00015-2","article-title":"Dopamine D-5 receptor modulates hippocampal acetylcholine release","volume":"76","author":"Hersi","year":"2000","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib31","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2006.11.048","article-title":"Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex","volume":"558","author":"Horner","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib32","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.103.053918","article-title":"Wake-promoting actions of dopamine D1 and D2 receptor stimulation","volume":"307","author":"Isaac","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0304-3940(03)00006-5","article-title":"Modafinil increases histamine release in the anterior hypothalamus of rats","volume":"339","author":"Ishizuka","year":"2003","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tins.2007.03.002","article-title":"Dopamine: 50 years in perspective","volume":"30","author":"Iversen","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neubiorev.2016.08.020","article-title":"Spontaneous eye blink rate as predictor of dopamine-related cognitive function-A review","volume":"71","author":"Jongkees","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib36","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/jpet.104.071092","article-title":"Effects of dopamine D1 ligands on eye blinking in monkeys: efficacy, antagonism, and D1\/D2 interactions","volume":"311","author":"Jutkiewicz","year":"2004","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib37","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.410120614","article-title":"Blink rates in parkinsonism","volume":"12","author":"Karson","year":"1982","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000341998","article-title":"Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis","volume":"11","author":"Kehagia","year":"2013","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/sj.npp.1300467","article-title":"Reduction in acetylcholine release in the hippocampus of dopamine D5 receptor-deficient mice","volume":"29","author":"Laplante","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1037\/h0053570","article-title":"Exploratory behavior and its relation to spontaneous alternation in a series of maze exposures","volume":"45","author":"Montgomery","year":"1952","journal-title":"J.\u00a0Compar. Physiol. Psychol."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0014-2999(89)90093-9","article-title":"The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1: D-2 interaction","volume":"160","author":"Murray","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1515\/revneuro-2013-0004","article-title":"Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease","volume":"24","author":"Narayanan","year":"2013","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/BF02244374","article-title":"Role of genotype and dopamine receptors in behaviour of inbred mice in a forced swimming test","volume":"105","author":"Nikulina","year":"1991","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neuroscience.2014.07.032","article-title":"Generating bursts (and pauses) in the dopamine midbrain neurons","volume":"282c","author":"Paladini","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-004-2048-7","article-title":"Forced swimming test in mice: a review of antidepressant activity","volume":"177","author":"Petit-Demouliere","year":"2005","journal-title":"Psychopharmacology"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2017.10.032_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","article-title":"Non-motor symptoms in Parkinson's disease","volume":"15","author":"Poewe","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib47","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4088\/JCP.12m08099","article-title":"Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial","volume":"74","author":"Rosenberg","year":"2013","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0022-3565(25)12045-4","article-title":"Alpha-2 adrenergic modulation of sleep: time-of-day-dependent pharmacodynamic profiles of dexmedetomidine and clonidine in the rat","volume":"275","author":"Seidel","year":"1995","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib49","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1126\/science.1075333","article-title":"Postsynaptic signaling and plasticity mechanisms","volume":"298","author":"Sheng","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib50","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","article-title":"Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study","volume":"72","author":"Slifstein","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib51","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1523\/JNEUROSCI.20-12-04480.2000","article-title":"Regulation of phosphorylation of the GluR1 AMPA receptor in the neostriatum by dopamine and psychostimulants in\u00a0vivo","volume":"20","author":"Snyder","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib52","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1111\/j.1460-9568.2007.05952.x","article-title":"Involvement of AMPA receptor phosphorylation in antidepressant actions with special reference to tianeptine","volume":"26","author":"Svenningsson","year":"2007","journal-title":"Eur. J. Neurosci."},{"issue":"supplement 1","key":"10.1016\/j.neuropharm.2017.10.032_bib53","first-page":"708","article-title":"Behavioral effects of a novel allosteric potentiator of the dopamine D1 receptor in human D1 knock-in mice and rhesus monkeys","volume":"30","author":"Svensson","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1124\/jpet.116.236372","article-title":"An allosteric potentiator of the dopamine D1 receptor increases locomotor activity in human D1 knock-in mice without causing stereotypy or tachyphylaxis","volume":"360","author":"Svensson","year":"2017","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib55","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.brainresbull.2009.12.004","article-title":"Selective D1 agonism but not D2 antagonism is reflected in cAMP and cGMP levels in rat CSF","volume":"81","author":"Torremans","year":"2010","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib56","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","article-title":"Implications of normal brain development for the pathogenesis of schizophrenia","volume":"44","author":"Weinberger","year":"1987","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib57","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/archpsyc.1988.01800310013001","article-title":"Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia: III. A new cohort and evidence for a monoaminergic mechanism","volume":"45","author":"Weinberger","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib58","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/syn.10043","article-title":"Evidence for activation of histamine H3 autoreceptors during handling stress in the prefrontal cortex of the rat","volume":"43","author":"Westerink","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib59","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200620060-00004","article-title":"Cognitive deficits and psychosis in Parkinson's disease","volume":"20","author":"Williams-Gray","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib60","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/gps.1788","article-title":"A\u00a0six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease\u2013rivastigmine patch versus capsule","volume":"22","author":"Winblad","year":"2007","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.10.032_bib61","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1124\/jpet.116.233627","article-title":"The rapidly acting antidepressant ketamine and the mGlu2\/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits","volume":"358","author":"Witkin","year":"2016","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib62","doi-asserted-by":"crossref","first-page":"8528","DOI":"10.1523\/JNEUROSCI.17-21-08528.1997","article-title":"Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance","volume":"17","author":"Zahrt","year":"1997","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.10.032_bib63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1523\/JNEUROSCI.20-16-j0001.2000","article-title":"Golf-alpha mediates dopamine D1 receptor signaling","volume":"20","author":"Zhuong","year":"2000","journal-title":"J.\u00a0Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304999?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817304999?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:20:10Z","timestamp":1750965610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817304999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":63,"alternative-id":["S0028390817304999"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.10.032","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.10.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Eli Lilly and Company. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}